Skip to main content

Table 6 5-year relative survival of non-metastatic breast cancer by age according to tumor subtype from 2011 to 2013 (CI 95%)

From: Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?

 

Triple negative

HER2 amplified

Luminal

 < 40 years

86,9% (75,6; 93,1)

99,6% (94,7; 99,9)

97% (94,7; 98,3)

40–49 years

87,4% (79,7; 92,3)

99,9% (96,1; 99,9)

98,6% (97,5; 99,1)

50–74 years

88,7% (83,1; 92,5)

95,1% (90,6; 97,5)

98,4% (97,5; 98,9)

 ≥ 75 years

84,2% (72; 91,4)

90,7% (79,7; 95,9)

94,4% (91,3; 96,4)